Genomic Health announces multiple studies highlighting important role of Oncotype DX in treating the underlying biology of early-stage breast cancer.

Genomic Health Inc announced results from seven new studies focusing on its multigene Oncotype DX breast cancer test, which has helped guide treatment decisions in more than 175,000 breast cancer patients worldwide. The data, presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), further confirm the clinical value associated with the Oncotype DX Recurrence Score in accurately predicting chemotherapy benefit and recurrence risk in early-stage breast cancer patients. Highlights from the seven studies presented by Genomic Health and research collaborators include: Meta-analysis of Seven Studies Reinforces Significance of Recurrence Score in Changing Treatment …